Tags

Type your tag names separated by a space and hit enter

Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
Exp Dermatol. 2017 11; 26(11):1143-1145.ED

Abstract

Brimonidine is a highly selective α2-adrenergic receptor agonist approved by the FDA for the treatment of rosacea. Rosacea is a major clinical disease with vasodilatation and rash on the centre of the face, and that brimonidine as a vasoconstrictor can act as a remedy for rosacea. However, there is no study of how brimonidine has an effect on rosacea-related immune cells or mechanisms in the skin to improve rosacea. In this study, we observed that clinical features of rosacea induced by LL-37 in Balb/c mice were improved after the application of brimonidine gel, and we also showed a marked decrease in the number of inflammatory cells, especially mast cells (MCs) histologically. Furthermore, we confirmed that mRNA levels of MC enzymes increased by LL-37 were reduced by brimonidine gel. To our knowledge, we first found that brimonidine has a mechanism of treating rosacea by reducing the number and mRNA levels of MC-specific enzymes, an important immune cell in the pathogenesis of rosacea.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

MeSH

Administration, CutaneousAdrenergic alpha-2 Receptor AgonistsAnimalsAntimicrobial Cationic PeptidesBrimonidine TartrateCell MovementDisease Models, AnimalEnzyme InductionEnzymesFemaleGelsMast CellsMiceRNA, MessengerRosacea

Pub Type(s)

Letter

Language

eng

PubMed ID

28500634

Citation

Kim, Miri, et al. "Inhibition of Mast Cell Infiltration in an LL-37-induced Rosacea Mouse Model Using Topical Brimonidine Tartrate 0.33% Gel." Experimental Dermatology, vol. 26, no. 11, 2017, pp. 1143-1145.

Kim M, Kim J, Jeong SW, et al. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Exp Dermatol. 2017;26(11):1143-1145.

Kim, M., Kim, J., Jeong, S. W., Jo, H., Woo, Y. R., & Park, H. J. (2017). Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Experimental Dermatology, 26(11), 1143-1145. https://doi.org/10.1111/exd.13381

Kim M, et al. Inhibition of Mast Cell Infiltration in an LL-37-induced Rosacea Mouse Model Using Topical Brimonidine Tartrate 0.33% Gel. Exp Dermatol. 2017;26(11):1143-1145. PubMed PMID: 28500634.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. AU - Kim,Miri, AU - Kim,Jongsic, AU - Jeong,Seo-Won, AU - Jo,Hyunmu, AU - Woo,Yu Ri, AU - Park,Hyun Jeong, Y1 - 2017/08/15/ PY - 2017/05/08/accepted PY - 2017/5/14/pubmed PY - 2018/7/22/medline PY - 2017/5/14/entrez KW - brimonidine KW - mast cell KW - rosacea SP - 1143 EP - 1145 JF - Experimental dermatology JO - Exp Dermatol VL - 26 IS - 11 N2 - Brimonidine is a highly selective α2-adrenergic receptor agonist approved by the FDA for the treatment of rosacea. Rosacea is a major clinical disease with vasodilatation and rash on the centre of the face, and that brimonidine as a vasoconstrictor can act as a remedy for rosacea. However, there is no study of how brimonidine has an effect on rosacea-related immune cells or mechanisms in the skin to improve rosacea. In this study, we observed that clinical features of rosacea induced by LL-37 in Balb/c mice were improved after the application of brimonidine gel, and we also showed a marked decrease in the number of inflammatory cells, especially mast cells (MCs) histologically. Furthermore, we confirmed that mRNA levels of MC enzymes increased by LL-37 were reduced by brimonidine gel. To our knowledge, we first found that brimonidine has a mechanism of treating rosacea by reducing the number and mRNA levels of MC-specific enzymes, an important immune cell in the pathogenesis of rosacea. SN - 1600-0625 UR - https://www.unboundmedicine.com/medline/citation/28500634/Inhibition_of_mast_cell_infiltration_in_an_LL_37_induced_rosacea_mouse_model_using_topical_brimonidine_tartrate_0_33_gel_ DB - PRIME DP - Unbound Medicine ER -